149 related articles for article (PubMed ID: 17241528)
21. Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
Kato N; Liang YQ; Ochiai Y; Birukawa N; Serizawa M; Jesmin S
Hypertens Res; 2008 Oct; 31(10):1963-75. PubMed ID: 19015604
[TBL] [Abstract][Full Text] [Related]
22. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
[TBL] [Abstract][Full Text] [Related]
23. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Iwai M; Chen R; Imura Y; Horiuchi M
Am J Hypertens; 2007 May; 20(5):579-86. PubMed ID: 17485025
[TBL] [Abstract][Full Text] [Related]
24. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
[TBL] [Abstract][Full Text] [Related]
25. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells.
Saitoh Y; Hongwei W; Ueno H; Mizuta M; Nakazato M
Diabetes Metab; 2009 Nov; 35(5):392-7. PubMed ID: 19713141
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Okazaki H; Minamino T; Tsukamoto O; Kim J; Okada K; Myoishi M; Wakeno M; Takashima S; Mochizuki N; Kitakaze M
Hypertens Res; 2006 Apr; 29(4):277-84. PubMed ID: 16778335
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells.
Wang HW; Mizuta M; Saitoh Y; Noma K; Ueno H; Nakazato M
Metabolism; 2011 Aug; 60(8):1081-9. PubMed ID: 21255808
[TBL] [Abstract][Full Text] [Related]
28. AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment.
Schupp N; Rutkowski P; Sebeková K; Klassen A; Bahner U; Grupp C; Heidland A; Stopper H
Kidney Blood Press Res; 2011; 34(3):167-72. PubMed ID: 21474964
[TBL] [Abstract][Full Text] [Related]
29. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
30. FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice.
Moon H; Chon J; Joo J; Kim D; In J; Lee H; Park J; Choi J
Diabetes Metab Res Rev; 2013 Jan; 29(1):19-24. PubMed ID: 22936676
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
[TBL] [Abstract][Full Text] [Related]
32. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study.
Ueki M; Koda M; Shimizu T; Mitsuta A; Yamamoto T; Murawaki Y
Hepatogastroenterology; 2009; 56(93):1100-4. PubMed ID: 19760950
[TBL] [Abstract][Full Text] [Related]
33. Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Huang Z; Jansson L; Sjöholm A
Clin Sci (Lond); 2008 Jul; 115(1):35-42. PubMed ID: 18205625
[TBL] [Abstract][Full Text] [Related]
34. Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice.
Zhao S; Chan LK; Chen L; Cheng TW; Klein T; Leung PS
Pancreas; 2016 Apr; 45(4):584-92. PubMed ID: 26495783
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling.
Kato T; Yamashita T; Sekiguchi A; Tsuneda T; Sagara K; Takamura M; Kaneko S; Aizawa T; Fu LT
J Cardiol; 2011 Sep; 58(2):131-6. PubMed ID: 21802905
[TBL] [Abstract][Full Text] [Related]
36. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
Ishiguro K; Sasamura H; Sakamaki Y; Itoh H; Saruta T
Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice.
Yamanaka M; Itakura Y; Inoue T; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Metabolism; 2006 Oct; 55(10):1286-92. PubMed ID: 16979397
[TBL] [Abstract][Full Text] [Related]
38. Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Yoshida S; Hashimoto T; Kihara M; Imai N; Yasuzaki H; Nomura K; Kiuchi Y; Tamura K; Ishigami T; Hirawa N; Toya Y; Kitamura H; Umemura S
Nephron Exp Nephrol; 2009; 111(1):e20-30. PubMed ID: 19052474
[TBL] [Abstract][Full Text] [Related]
39. Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure.
Vaile JC; Chowdhary S; Osman F; Ross HF; Fletcher J; Littler WA; Coote JH; Townend JN
Clin Sci (Lond); 2001 Dec; 101(6):559-66. PubMed ID: 11724639
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice.
Chu KY; Leung PS
Antioxid Redox Signal; 2007 Jul; 9(7):869-78. PubMed ID: 17508912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
